Term
| 6 "positive"sx in psychosis: |
|
Definition
1. delusions
2. disorganized speach
3. hallucinations
4. catatonic behavior
5. aggression
6. paranoia |
|
|
Term
| 5 "negative" sx of psychosis: |
|
Definition
1. Alogia (poverty of speach)
2. Avolition (lack of motivation)
3. flattened affect
4. anhedonia (inability to exper pleasure)
5. social isolation |
|
|
Term
| 3 low potency typical antipsychotics: |
|
Definition
1. chloropromazine
2. thioridazine
3. mesoridazine |
|
|
Term
| 5 mid-potency typical antipsychotics; |
|
Definition
1. molindone
2. loxapine
3. perphenazine
4. trifuoperazine
5. thiothixene |
|
|
Term
| 2 high potency typical antipsychotics: |
|
Definition
1. Haloperidol
2. Fluphenazine |
|
|
Term
| typical antipsychotics are of most benefit w pos or neg sx? |
|
Definition
| most benefit w positive sx |
|
|
Term
| high dose typical antipsychotics may worsen: |
|
Definition
|
|
Term
| first line tx for schizophrenia: |
|
Definition
| atypical antipsychotics EXCLUDING clozapine and ziprasidone |
|
|
Term
| warning regaurding the development or worsening of _______ applies to ALL atypical antipsychotics. |
|
Definition
| atypical antipsychotics may cause the development or worsening of existing Diabetes |
|
|
Term
| indications for clozepine: |
|
Definition
1. NOT a first line
2. for tx-resistant pts failing at least 2 other meds
3. especially helpful in aggression
4. PD pts with psychosis (low dose) |
|
|
Term
| which med causes agranulocytosis" |
|
Definition
|
|
Term
common SE of clozepine 6:
; |
|
Definition
1. silorrhea
2. sedation
3. constipation
4. orthostatic hypotension
5. seizures
6. weight gain |
|
|
Term
| there is a 30-60% risk for pts on antipsychotics to develop EPS such as: |
|
Definition
1. akathesia
2. acute dystonia
3. pseudoparkinsonism
4. tardive dyskinesia |
|
|
Term
|
Definition
|
|
Term
| medication related RF for development of EPS: |
|
Definition
1. high potency
2. large dose
3. parenteral route of admin
4. most often seen in young males |
|
|
Term
| EPS that occurs wn 1wk of antipsychotic therapy: |
|
Definition
| acute dystonia (<1wk) & pseudoparkinsonism (1wk) |
|
|
Term
| EPS that occurs wn 1wk of antipsychotic therapy: |
|
Definition
| acute dystonia (<1wk) & pseudoparkinsonism (1wk) |
|
|
Term
|
Definition
1. benztropine 2mg
2. diphenhydramine 50mg
3. lorazepam 2mg |
|
|
Term
| pseudoparkinsonism tx can include any of the EPS tx plus: |
|
Definition
|
|
Term
|
Definition
1. reduce antipsychotic does if possible
2. propanolol
3. lorazepam |
|
|
Term
| 3 types of tardive dyskinesia: |
|
Definition
1. facial (first sx is tongue)
2. extremities (chorea)
3. Truncal (unusual posture) |
|
|
Term
| tardive dyskinesia is a complication of: |
|
Definition
| long term antipsychotic use (years) |
|
|
Term
| 2 methods of prevention for tardive dyskinesia: |
|
Definition
1. drug holidays
2. use of atypical antipsychotics(contraversial) |
|
|
Term
| 4 RF for development of tardive dyskinesia: |
|
Definition
1. increased age
2. long duration of therapy
3. high potency antipsychotics
4. high antipsychotic doses |
|
|
Term
| tx of tardive dyskinesia: |
|
Definition
1. reduce dose
2. change medication if possible |
|
|
Term
| rapidly progressing over 24-72hrs, can occur at any time, with any dose of antipsychotic: fvr, tachy, arrhythmias, ALOC, rigidity, >WBC,>CPK |
|
Definition
|
|
Term
| tx of neuromalignant syndrome: |
|
Definition
| d/c offending agent and institute supportive care |
|
|
Term
| antipsychotic available for depot formulations: |
|
Definition
|
|
Term
| 3 general parameters for use of depot formulations: |
|
Definition
1. given on a monthly schedule
2. must be stable on oral dose prior to conversion
3. d/c oral dose after initiating loading method |
|
|
